CalciMedica’s CRAC inhibitor Auxora™ shows promise as a treatment for severe COVID-19 pneumonia

BY      |     July 16, 2020

CalciMedica, a clinical-stage biotechnology company developing CRAC inhibitors for the treatment of inflammatory diseases, announced results from their Phase 2 randomized, controlled, open-label clinical trial evaluating the CRAC inhibitor Auxora™ (also known as CM4620-IE) for the treatment of severe COVID-19 pneumonia.

Auxora™, when combined with standard therapy, improved outcomes in patients with severe COVID-19 pneumonia showing faster recovery and reduced use of invasive mechanical ventilation and death as compared to standard therapy alone. Auxora also showed a favorable safety profile.

CalciMedica plans to move to a randomized, blinded, placebo-controlled study of Auxora™ in the coming weeks.

Read the press release here.

Read more about CalciMedica here.

Photo by CDC on Unsplash

Comments? Questions? Suggestions?

If you have any comments, questions or suggestions concerning this article, feel free to email me at
Alternatively, you can leave your comments on LinkedIn or Twitter.